)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CytoMed Therapeutics
CytoMed Therapeutics (GDTC) investor relations material
CytoMed Therapeutics H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary31 Mar, 2026
Executive summary
Clinical-stage biopharma focused on allogeneic, off-the-shelf cell-based immunotherapies for cancer and degenerative diseases, with five product candidates in development: CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK.
Lead candidate CTM-N2D is in Phase I clinical trial (ANGELICA Trial) in Singapore; other candidates are in preclinical or IND-enabling stages.
Expanded into private blood banking services in Malaysia, leveraging acquired assets and licenses.
Financial highlights
No revenue from approved cell therapies; revenue generated from private blood banking services and research income (cost recovery basis).
FY2025 revenue: S$252,265 (down from S$324,387 in 2024); research income increased to S$536,461.
Net loss for FY2025: S$4.00 million (vs. S$2.52 million in 2024); loss would be S$2.72 million excluding non-cash share-based payments and public company costs.
Cash and bank balances at year-end 2025: S$2.10 million (down from S$4.97 million in 2024).
Research expenses rose to S$2.22 million in 2025 (from S$1.91 million in 2024), driven by higher consumables, employee benefits, and clinical trial costs.
Share-based compensation of S$694,200 recognized in 2025.
Outlook and guidance
Expect continued losses as R&D and clinical activities expand; future profitability dependent on successful product development and commercialization.
Ongoing ATM equity offering and potential additional financings to support operations; no commitments for further financing as of year-end.
Focus on advancing clinical trials for CTM-N2D and CTM-GDT, and preclinical development for other candidates.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CytoMed Therapeutics
- Biopharma innovator seeks up to $50M for allogeneic cell therapy pipeline and clinical expansion.GDTC
Registration Filing - Net loss increased on higher R&D and share-based costs, with first revenue from cord blood banking.GDTCH1 2025
- Transitioning to clinical stage in Q4 2024 with strong cash and new cord blood assets.GDTCH1 2024
- Net loss narrowed 39% as clinical and corporate expansion accelerated in 2024.GDTCH2 2024
Next CytoMed Therapeutics earnings date
H1 20265 Nov, 2026
CytoMed Therapeutics
Next CytoMed Therapeutics earnings date
H1 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CytoMed Therapeutics Limited is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company leverages advanced cellular technology to create novel therapeutic solutions that harness the immune system’s capabilities to target and eliminate cancer cells. CytoMed's research and development efforts concentrate on proprietary cell therapy platforms that aim to offer effective, potentially less toxic alternatives to conventional cancer treatments. CytoMed Therapeutics Limited is headquartered in Singapore, and its shares are listed on the NASDAQ.